194 related articles for article (PubMed ID: 20808304)
1. Psoriasis: Is ustekinumab superior to etanercept for psoriasis?
Kuhn A; Luger TA
Nat Rev Rheumatol; 2010 Sep; 6(9):500-1. PubMed ID: 20808304
[No Abstract] [Full Text] [Related]
2. Dermatologist preferences for treatments to compare in future randomized controlled comparative effectiveness trials for moderate to severe psoriasis.
Wan J; Abuabara K; Troxel AB; Shin DB; Van Voorhees AS; Bebo BF; Krueger GG; Callis Duffin K; Gelfand JM
Arch Dermatol; 2012 Apr; 148(4):539-41. PubMed ID: 22508884
[No Abstract] [Full Text] [Related]
3. Ustekinumab for the treatment of psoriasis: review of three multicenter clinical trials.
Farhi D
Drugs Today (Barc); 2010 Apr; 46(4):259-64. PubMed ID: 20502723
[TBL] [Abstract][Full Text] [Related]
4. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
[TBL] [Abstract][Full Text] [Related]
5. Ustekinumab for the treatment of psoriasis.
Laws PM; Warren RB
Expert Rev Clin Immunol; 2011 Mar; 7(2):155-64. PubMed ID: 21426253
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic management of plaque psoriasis: the interest of anti-TNFalpha].
Ortonne JP
Ann Dermatol Venereol; 2005; 132(8-9 Pt 2):4S6-4S9. PubMed ID: 16335346
[No Abstract] [Full Text] [Related]
7. Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis.
Girolomoni G; Abeni D
Arch Dermatol; 2001 Jun; 137(6):784-5. PubMed ID: 11405771
[No Abstract] [Full Text] [Related]
8. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
Mössner R; Reich K
Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.
Uhlenhake EE; Feldman SR
Expert Opin Biol Ther; 2010 Jul; 10(7):1105-12. PubMed ID: 20446825
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus complicating biological immunosuppressive therapy in two patients with psoriasis receiving treatment with etanercept or efalizumab.
Petersen B; Lorentzen H
Acta Derm Venereol; 2008; 88(5):523-4. PubMed ID: 18779901
[No Abstract] [Full Text] [Related]
11. Successful use of infliximab following a failed course of etanercept in a pediatric patient.
Farnsworth NN; George SJ; Hsu S
Dermatol Online J; 2005 Dec; 11(3):11. PubMed ID: 16409907
[No Abstract] [Full Text] [Related]
12. Adalimumab vs. etanercept in psoriasis.
Downs AM
Clin Exp Dermatol; 2007 Sep; 32(5):593. PubMed ID: 17692064
[No Abstract] [Full Text] [Related]
13. Immunologic targets in psoriasis.
Kupper TS
N Engl J Med; 2003 Nov; 349(21):1987-90. PubMed ID: 14627782
[No Abstract] [Full Text] [Related]
14. Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective.
Pan F; Brazier NC; Shear NH; Jivraj F; Schenkel B; Brown R
Value Health; 2011; 14(5):652-6. PubMed ID: 21839402
[TBL] [Abstract][Full Text] [Related]
15. Ustekinumab: new drug. Suspicion of carcinogenicity: too great a risk for psoriasis patients.
Prescrire Int; 2009 Oct; 18(103):202-4. PubMed ID: 19882785
[TBL] [Abstract][Full Text] [Related]
16. The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients.
Young MS; Horn EJ; Cather JC
Expert Rev Clin Immunol; 2011 Jan; 7(1):9-13. PubMed ID: 21162644
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
Reich K; Burden AD; Eaton JN; Hawkins NS
Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
[TBL] [Abstract][Full Text] [Related]
18. Antidrug antibodies in psoriasis: a systematic review.
Hsu L; Snodgrass BT; Armstrong AW
Br J Dermatol; 2014 Feb; 170(2):261-73. PubMed ID: 24117166
[TBL] [Abstract][Full Text] [Related]
19. Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment.
Van L; Modi SV; Yang DJ; Hsu S
Arch Dermatol; 2008 Jun; 144(6):804-6. PubMed ID: 18559778
[No Abstract] [Full Text] [Related]
20. Etanercept in psoriasis treatment.
Pietrzak A; Chodorowska G; Urban J; Roliński J; Pietrzak B
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):222-6. PubMed ID: 15314989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
